CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance
[3];
[3];
[3];
more »
- Univ. of Texas, Houston, TX (United States). MD Anderson Cancer Center
- Univ. of Texas, Houston, TX (United States). MD Anderson Cancer Center; Univ. of Wisconsin, Milwaukee, WI (United States)
- Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
- Univ. of Texas, Houston, TX (United States). MD Anderson Cancer Center; Stanford Univ., CA (United States)
- Univ. of Miami, Miami, FL (United States)
Despite wide use of anti-vascular endothelial growth factor (VEGF) therapy for many solid 30 cancers, most of them become resistant to this therapy and develop into progressive disease. 31 Therefore, new biomarkers and strategies for blocking adaptive resistance of cancer to anti-VEGF therapy are needed. As described herein, we found that cancer-derived small extracellular vesicles (EVs) package increasing quantities of VEGF and other factors in response to anti-VEGF therapy. Notably, small EV-VEGF (eVEGF) is not recognized by bevacizumab and can be transferred to endothelial cells and trigger intracrine signaling and promote angiogenesis. Also, serum eVEGF was present at higher levels in ovarian cancer mouse models with adaptive resistance to bevacizumab than in models sensitive to it. Ovarian cancer cell-derived eVEGF increased tumor growth despite treatment with bevacizumab. Notably, the eVEGF level was elevated in patient serum after bevacizumab-containing therapy. Proteomic data of small EVs from mouse models suggested that several novel biomarkers are promising for drug response prediction. Collectively, these data demonstrated a new mechanism whereby eVEGF evades recognition by therapeutic antibodies and promotes tumor angiogenesis and progression. These findings have clinical implications for biomarkers and new therapeutic strategies for ovarian cancer.
- Research Organization:
- Pacific Northwest National Laboratory (PNNL), Richland, WA (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC)
- Grant/Contract Number:
- AC05-76RL01830
- OSTI ID:
- 1836250
- Report Number(s):
- PNNL-SA--154216
- Journal Information:
- Cell Reports, Journal Name: Cell Reports Journal Issue: 7 Vol. 36; ISSN 2211-1247
- Publisher:
- ElsevierCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Comparing protein VEGF inhibitors: In vitro biological studies
VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells